Amphastar Pharmaceuticals Key Executives
This section highlights Amphastar Pharmaceuticals's key executives, including their titles and compensation details.
Find Contacts at Amphastar Pharmaceuticals
(Showing 0 of )
Amphastar Pharmaceuticals Earnings
This section highlights Amphastar Pharmaceuticals's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-02-27 | $1.01 | $0.92 |
| Read Transcript | Q3 | 2024 | 2024-11-06 | $0.99 | $0.96 |
| Read Transcript | Q1 | 2024 | 2024-05-08 | $0.96 | $1.04 |
| Read Transcript | Q4 | 2023 | 2024-02-29 | N/A | N/A |
| Read Transcript | Q3 | 2023 | 2023-11-08 | $0.69 | $1.15 |
| Read Transcript | Q2 | 2023 | 2023-08-08 | $0.56 | $0.65 |
| Read Transcript | Q1 | 2023 | 2023-05-13 | N/A | N/A |
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
$23.75
Stock Price
$1.13B
Market Cap
2.03K
Employees
Rancho Cucamonga, CA
Location
Financial Statements
Access annual & quarterly financial statements for Amphastar Pharmaceuticals, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $712.81M | $644.39M | $498.99M | $437.77M | $349.85M |
| Cost of Revenue | $338.96M | $293.27M | $250.13M | $238.03M | $206.51M |
| Gross Profit | $373.86M | $351.12M | $248.86M | $199.74M | $143.34M |
| Gross Profit Ratio | 52.45% | 54.49% | 49.87% | 45.63% | 40.97% |
| Research and Development Expenses | $73.91M | $73.74M | $74.77M | $60.93M | $67.23M |
| General and Administrative Expenses | $56.72M | $51.54M | $45.06M | $51.43M | $50.38M |
| Selling and Marketing Expenses | $37.80M | $28.85M | $21.53M | $17.49M | $14.78M |
| Selling General and Administrative Expenses | $94.52M | $80.39M | $66.59M | $68.92M | $65.16M |
| Other Expenses | $- | $- | $8.54M | $14.25M | $-6.32M |
| Operating Expenses | $168.44M | $154.13M | $141.36M | $129.85M | $132.39M |
| Cost and Expenses | $507.39M | $447.41M | $391.49M | $367.88M | $338.89M |
| Interest Income | $10.61M | $5.46M | $1.32M | $601.00K | $642.00K |
| Interest Expense | $30.34M | $27.16M | $1.85M | $885.00K | $374.00K |
| Depreciation and Amortization | $57.20M | $41.78M | $28.74M | $26.75M | $25.18M |
| EBITDA | $277.31M | $240.29M | $107.50M | $111.78M | $30.19M |
| EBITDA Ratio | 38.90% | 37.29% | 21.54% | 25.53% | 8.63% |
| Operating Income | $205.42M | $196.99M | $78.76M | $43.13M | $-14.23M |
| Operating Income Ratio | 28.82% | 30.57% | 15.78% | 9.85% | -4.07% |
| Total Other Income Expenses Net | $-15.65M | $-25.63M | $8.54M | $14.25M | $-6.32M |
| Income Before Tax | $189.76M | $171.36M | $116.04M | $84.14M | $4.64M |
| Income Before Tax Ratio | 26.62% | 26.59% | 23.26% | 19.22% | 1.33% |
| Income Tax Expense | $29.67M | $31.83M | $23.48M | $20.63M | $3.54M |
| Net Income | $159.52M | $137.54M | $91.39M | $62.12M | $1.10M |
| Net Income Ratio | 22.38% | 21.34% | 18.31% | 14.19% | 0.31% |
| EPS | $3.29 | $2.85 | $1.88 | $1.30 | $0.02 |
| EPS Diluted | $3.06 | $2.60 | $1.74 | $1.25 | $0.02 |
| Weighted Average Shares Outstanding | 48.43M | 48.27M | 48.55M | 47.78M | 47.04M |
| Weighted Average Shares Outstanding Diluted | 52.06M | 53.00M | 52.43M | 49.78M | 49.12M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $186.98M | $188.82M | $182.39M | $171.84M | $178.10M | $180.56M | $145.71M | $140.02M | $135.02M | $120.13M | $123.47M | $120.37M | $120.89M | $112.20M | $101.66M | $103.02M | $95.92M | $83.43M | $85.81M | $84.69M |
| Cost of Revenue | $100.33M | $86.88M | $90.35M | $84.55M | $84.54M | $72.15M | $72.97M | $66.18M | $63.85M | $61.62M | $60.11M | $64.54M | $64.65M | $61.02M | $54.29M | $58.07M | $59.09M | $46.92M | $52.63M | $47.87M |
| Gross Profit | $86.65M | $101.94M | $92.05M | $87.29M | $93.57M | $108.40M | $72.74M | $73.84M | $71.17M | $58.51M | $63.36M | $55.83M | $56.23M | $51.18M | $47.38M | $44.95M | $36.83M | $36.51M | $33.18M | $36.82M |
| Gross Profit Ratio | 46.34% | 53.99% | 50.47% | 50.80% | 52.53% | 60.04% | 49.92% | 52.73% | 52.71% | 48.71% | 51.31% | 46.38% | 46.52% | 45.62% | 46.60% | 43.63% | 38.40% | 43.76% | 38.67% | 43.48% |
| Research and Development Expenses | $18.14M | $21.08M | $14.53M | $14.23M | $17.85M | $16.66M | $16.84M | $19.82M | $17.24M | $18.51M | $22.80M | $16.22M | $17.29M | $10.76M | $18.12M | $14.77M | $18.13M | $17.64M | $16.15M | $15.30M |
| General and Administrative Expenses | $12.94M | $14.82M | $13.29M | $15.68M | $13.12M | $12.65M | $12.28M | $13.48M | $10.63M | $11.98M | $9.98M | $12.47M | $10.62M | $10.91M | $14.56M | $15.34M | $12.03M | $11.67M | $15.92M | $10.75M |
| Selling and Marketing Expenses | $10.42M | $8.99M | $9.01M | $9.37M | $8.62M | $6.41M | $6.72M | $7.11M | $5.47M | $4.78M | $5.76M | $5.52M | $4.08M | $4.75M | $4.13M | $4.54M | $3.79M | $3.67M | $4.03M | $3.29M |
| Selling General and Administrative Expenses | $23.36M | $23.82M | $22.30M | $25.05M | $21.74M | $19.06M | $19.00M | $20.59M | $16.10M | $16.77M | $15.73M | $17.99M | $14.70M | $15.65M | $18.69M | $19.88M | $15.82M | $15.35M | $19.95M | $14.04M |
| Other Expenses | $- | $- | $298.00K | $5.92M | $-5.48M | $-9.04M | $-4.09M | $136.00K | $3.43M | $-632.00K | $-1.67M | $7.59M | $2.91M | $12.88M | $3.60M | $-5.25M | $-9.62M | $3.58M | $1.42M | $-1.68M |
| Operating Expenses | $41.50M | $44.89M | $36.83M | $39.28M | $39.59M | $35.73M | $35.84M | $40.41M | $33.34M | $35.28M | $38.53M | $34.21M | $31.98M | $26.41M | $36.82M | $34.64M | $33.95M | $32.99M | $36.10M | $29.34M |
| Cost and Expenses | $141.83M | $131.77M | $127.18M | $123.83M | $124.12M | $107.88M | $108.82M | $106.59M | $97.19M | $96.90M | $98.64M | $98.75M | $96.64M | $87.43M | $91.10M | $92.71M | $93.04M | $79.91M | $88.73M | $77.21M |
| Interest Income | $2.29M | $2.43M | $3.34M | $2.56M | $2.30M | $1.20M | $1.03M | $924.00K | $580.00K | $331.00K | $229.00K | $181.00K | $157.00K | $141.00K | $142.00K | $161.00K | $130.00K | $161.00K | $198.00K | $153.00K |
| Interest Expense | $6.42M | $6.70M | $8.61M | $8.61M | $9.46M | $13.70M | $3.60M | $398.00K | $528.00K | $566.00K | $397.00K | $355.00K | $168.00K | $527.00K | $86.00K | $104.00K | $88.00K | $175.00K | $35.00K | $76.00K |
| Depreciation and Amortization | $14.66M | $14.43M | $14.14M | $13.96M | $13.79M | $13.57M | $7.02M | $7.40M | $7.43M | $7.49M | $7.02M | $6.79M | $6.55M | $6.51M | $6.87M | $6.83M | $6.77M | $6.67M | $5.92M | $5.82M |
| EBITDA | $65.05M | $68.81M | $69.36M | $61.97M | $67.77M | $90.91M | $43.43M | $41.36M | $49.22M | $23.23M | $24.82M | $36.18M | $33.88M | $44.68M | $21.17M | $12.04M | $116.00K | $13.92M | $4.45M | $11.70M |
| EBITDA Ratio | 34.79% | 36.44% | 38.03% | 36.07% | 38.05% | 50.35% | 29.81% | 29.54% | 36.45% | 19.34% | 20.10% | 30.06% | 28.03% | 39.83% | 20.82% | 11.69% | 0.12% | 16.69% | 5.18% | 13.82% |
| Operating Income | $45.14M | $57.05M | $55.22M | $48.01M | $53.98M | $72.68M | $36.90M | $26.04M | $37.83M | $15.74M | $24.82M | $29.39M | $24.25M | $24.77M | $10.56M | $10.31M | $2.88M | $3.52M | $-2.92M | $7.48M |
| Operating Income Ratio | 24.14% | 30.21% | 30.27% | 27.94% | 30.31% | 40.25% | 25.32% | 18.59% | 28.02% | 13.10% | 20.10% | 24.42% | 20.06% | 22.08% | 10.39% | 10.00% | 3.00% | 4.22% | -3.41% | 8.83% |
| Total Other Income Expenses Net | $-1.18M | $-9.37M | $-4.97M | $-134.00K | $-12.63M | $-9.04M | $-4.09M | $136.00K | $3.43M | $-632.00K | $-1.67M | $7.42M | $2.91M | $12.88M | $3.66M | $-5.19M | $-9.62M | $3.56M | $1.42M | $-1.68M |
| Income Before Tax | $43.96M | $47.68M | $50.24M | $47.88M | $41.34M | $63.64M | $32.81M | $33.57M | $41.26M | $22.60M | $23.15M | $29.03M | $27.16M | $37.65M | $14.22M | $5.11M | $-6.74M | $7.08M | $-1.50M | $5.80M |
| Income Before Tax Ratio | 23.51% | 25.25% | 27.55% | 27.86% | 23.21% | 35.25% | 22.52% | 23.97% | 30.56% | 18.81% | 18.75% | 24.12% | 22.47% | 33.55% | 13.98% | 4.96% | -7.03% | 8.48% | -1.75% | 6.85% |
| Income Tax Expense | $6.00M | $7.25M | $12.29M | $4.13M | $4.67M | $14.03M | $6.38M | $6.75M | $7.29M | $6.56M | $5.55M | $4.08M | $7.19M | $6.69M | $5.59M | $1.16M | $-950.00K | $2.29M | $-75.00K | $2.28M |
| Net Income | $37.96M | $40.43M | $37.95M | $43.18M | $36.17M | $49.22M | $26.12M | $26.03M | $33.91M | $15.87M | $17.35M | $24.25M | $19.76M | $29.55M | $7.77M | $5.04M | $-6.27M | $3.92M | $-192.00K | $3.95M |
| Net Income Ratio | 20.30% | 21.41% | 20.81% | 25.13% | 20.31% | 27.26% | 17.93% | 18.59% | 25.12% | 13.21% | 14.05% | 20.15% | 16.35% | 26.34% | 7.64% | 4.89% | -6.54% | 4.70% | -0.22% | 4.66% |
| EPS | $0.79 | $0.83 | $0.78 | $0.90 | $0.75 | $1.01 | $0.54 | $0.54 | $0.70 | $0.30 | $0.35 | $0.47 | $0.41 | $0.62 | $0.16 | $0.11 | $-0.13 | $0.08 | $0.00 | $0.09 |
| EPS Diluted | $0.74 | $0.78 | $0.73 | $0.81 | $0.68 | $0.91 | $0.49 | $0.50 | $0.66 | $0.30 | $0.33 | $0.47 | $0.39 | $0.59 | $0.16 | $0.10 | $-0.13 | $0.08 | $0.00 | $0.08 |
| Weighted Average Shares Outstanding | 47.98M | 48.62M | 48.91M | 48.21M | 47.96M | 48.70M | 48.40M | 48.00M | 48.30M | 52.79M | 48.86M | 51.60M | 47.84M | 48.02M | 47.73M | 47.52M | 46.89M | 47.50M | 46.75M | 46.41M |
| Weighted Average Shares Outstanding Diluted | 51.31M | 51.86M | 52.05M | 53.01M | 53.01M | 53.92M | 53.10M | 51.97M | 51.72M | 52.79M | 53.23M | 51.98M | 50.06M | 50.01M | 49.55M | 49.52M | 47.50M | 49.85M | 46.75M | 48.25M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $151.61M | $144.30M | $156.10M | $126.35M | $92.64M |
| Short Term Investments | $70.04M | $112.51M | $19.66M | $10.32M | $12.98M |
| Cash and Short Term Investments | $221.65M | $256.81M | $175.76M | $136.67M | $105.62M |
| Net Receivables | $138.04M | $114.94M | $88.80M | $78.80M | $66.00M |
| Inventory | $153.74M | $105.83M | $103.58M | $92.81M | $96.83M |
| Other Current Assets | $20.65M | $12.02M | $17.73M | $9.84M | $11.23M |
| Total Current Assets | $534.07M | $489.60M | $378.32M | $318.12M | $279.68M |
| Property Plant Equipment Net | $344.63M | $315.64M | $264.57M | $271.49M | $280.71M |
| Goodwill | $3.05M | $3.22M | $3.13M | $3.31M | $3.94M |
| Intangible Assets | $587.61M | $610.08M | $34.17M | $35.56M | $36.67M |
| Goodwill and Intangible Assets | $590.66M | $613.29M | $37.30M | $38.87M | $40.62M |
| Long Term Investments | $11.00M | $15.21M | $2.41M | $3.98M | $- |
| Tax Assets | $71.12M | $53.25M | $38.53M | $22.40M | $24.98M |
| Other Non-Current Assets | $25.99M | $25.91M | $20.86M | $16.66M | $5.25M |
| Total Non-Current Assets | $1.04B | $1.02B | $363.67M | $353.41M | $351.55M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $1.58B | $1.51B | $741.99M | $671.53M | $631.24M |
| Account Payables | $30.51M | $25.44M | $20.50M | $22.21M | $24.36M |
| Short Term Debt | $7.04M | $4.34M | $9.05M | $8.17M | $18.98M |
| Tax Payables | $1.75M | $1.61M | $4.57M | $9.08M | $1.08M |
| Deferred Revenue | $- | $- | $- | $- | $- |
| Other Current Liabilities | $134.46M | $194.02M | $60.74M | $64.35M | $67.79M |
| Total Current Liabilities | $173.76M | $225.41M | $94.86M | $103.81M | $112.20M |
| Long Term Debt | $643.51M | $619.30M | $96.53M | $99.48M | $51.65M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $6.96M | $- | $7.37M | $7.07M | $5.45M |
| Other Non-Current Liabilities | $20.95M | $28.78M | $21.79M | $22.18M | $17.92M |
| Total Non-Current Liabilities | $671.41M | $648.08M | $118.47M | $122.20M | $70.31M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $845.17M | $873.49M | $213.33M | $226.01M | $182.51M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $6.00K | $6.00K | $6.00K | $6.00K | $5.00K |
| Retained Earnings | $568.79M | $409.27M | $271.72M | $180.34M | $117.77M |
| Accumulated Other Comprehensive Income Loss | $-9.18M | $-8.48M | $-8.62M | $-6.76M | $-3.72M |
| Other Total Stockholders Equity | $172.69M | $238.62M | $265.55M | $271.94M | $288.25M |
| Total Stockholders Equity | $732.30M | $639.42M | $528.66M | $445.52M | $402.31M |
| Total Equity | $732.30M | $639.42M | $528.66M | $445.52M | $448.72M |
| Total Liabilities and Stockholders Equity | $1.58B | $1.51B | $741.99M | $671.53M | $631.24M |
| Minority Interest | $- | $- | $- | $- | $46.42M |
| Total Liabilities and Total Equity | $1.58B | $1.51B | $741.99M | $671.53M | $631.24M |
| Total Investments | $81.03M | $127.72M | $22.08M | $14.30M | $12.98M |
| Total Debt | $650.55M | $623.64M | $102.58M | $104.66M | $67.27M |
| Net Debt | $498.94M | $479.35M | $-53.52M | $-21.69M | $-25.37M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $151.61M | $192.12M | $189.62M | $201.15M | $144.53M | $266.78M | $148.59M | $176.62M | $156.10M | $157.24M | $166.16M | $172.63M | $126.35M | $106.61M | $105.43M | $101.60M | $92.64M | $87.91M | $87.39M | $54.84M |
| Short Term Investments | $70.04M | $58.38M | $28.16M | $88.41M | $114.71M | $33.10M | $14.54M | $16.28M | $19.66M | $26.84M | $17.23M | $14.38M | $10.32M | $8.02M | $11.74M | $13.53M | $12.98M | $10.87M | $11.10M | $12.20M |
| Cash and Short Term Investments | $221.65M | $250.49M | $217.78M | $289.56M | $259.24M | $299.88M | $163.14M | $192.89M | $175.76M | $184.09M | $183.39M | $187.01M | $136.67M | $114.63M | $117.18M | $115.13M | $105.62M | $98.78M | $98.49M | $67.05M |
| Net Receivables | $138.04M | $144.98M | $132.08M | $138.90M | $114.94M | $118.99M | $104.72M | $100.64M | $88.80M | $77.10M | $80.81M | $73.17M | $78.80M | $78.09M | $67.89M | $77.94M | $66.00M | $52.38M | $49.86M | $57.78M |
| Inventory | $153.74M | $130.32M | $122.41M | $115.49M | $105.83M | $109.98M | $104.62M | $103.65M | $103.58M | $103.25M | $98.73M | $95.15M | $92.81M | $100.24M | $97.93M | $97.11M | $96.83M | $108.87M | $104.73M | $107.90M |
| Other Current Assets | $20.65M | $20.16M | $10.38M | $11.13M | $21.07M | $20.36M | $17.96M | $17.82M | $17.73M | $19.79M | $14.21M | $9.09M | $9.84M | $10.71M | $27.97M | $9.98M | $11.23M | $16.51M | $13.74M | $13.99M |
| Total Current Assets | $534.07M | $545.95M | $482.64M | $555.08M | $489.60M | $543.00M | $384.55M | $407.67M | $378.32M | $384.22M | $377.14M | $364.42M | $318.12M | $303.67M | $310.97M | $300.16M | $279.68M | $276.54M | $266.82M | $246.72M |
| Property Plant Equipment Net | $344.63M | $327.52M | $320.57M | $320.39M | $315.64M | $314.11M | $305.51M | $269.99M | $264.57M | $259.80M | $264.73M | $271.37M | $271.49M | $271.01M | $280.30M | $273.14M | $280.71M | $266.83M | $256.10M | $250.21M |
| Goodwill | $3.05M | $3.26M | $3.13M | $3.15M | $3.22M | $3.09M | $3.17M | $3.17M | $3.13M | $2.89M | $3.05M | $3.26M | $3.31M | $3.39M | $3.84M | $3.79M | $3.94M | $3.77M | $3.63M | $3.57M |
| Intangible Assets | $587.61M | $591.54M | $597.72M | $603.91M | $610.08M | $616.26M | $622.44M | $34.00M | $34.17M | $34.15M | $34.65M | $35.18M | $35.56M | $35.81M | $36.21M | $36.45M | $36.67M | $36.60M | $36.64M | $36.90M |
| Goodwill and Intangible Assets | $590.66M | $594.80M | $600.85M | $607.06M | $613.29M | $619.35M | $625.60M | $37.18M | $37.30M | $37.04M | $37.70M | $38.44M | $38.87M | $39.19M | $40.05M | $40.24M | $40.62M | $40.38M | $40.27M | $40.47M |
| Long Term Investments | $11.00M | $- | $9.94M | $15.16M | $15.21M | $2.00M | $1.46M | $1.76M | $2.41M | $2.69M | $3.06M | $3.32M | $3.98M | $4.19M | $- | $- | $- | $- | $- | $- |
| Tax Assets | $71.12M | $53.25M | $53.25M | $53.25M | $53.25M | $40.87M | $40.87M | $38.53M | $38.53M | $22.40M | $22.40M | $22.40M | $22.40M | $22.00M | $24.98M | $24.98M | $24.98M | $22.23M | $24.23M | $24.23M |
| Other Non-Current Assets | $25.99M | $23.66M | $24.26M | $23.37M | $25.91M | $25.30M | $20.27M | $18.54M | $20.86M | $20.55M | $18.68M | $16.30M | $16.66M | $11.61M | $9.44M | $7.21M | $5.25M | $7.74M | $12.63M | $11.19M |
| Total Non-Current Assets | $1.04B | $999.23M | $1.01B | $1.02B | $1.02B | $1.00B | $993.71M | $365.99M | $363.67M | $342.47M | $346.57M | $351.82M | $353.41M | $348.01M | $354.77M | $345.57M | $351.55M | $337.18M | $333.24M | $326.11M |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $1.58B | $1.55B | $1.49B | $1.57B | $1.51B | $1.54B | $1.38B | $773.66M | $741.99M | $726.70M | $723.72M | $716.24M | $671.53M | $651.68M | $665.75M | $645.74M | $631.24M | $613.72M | $600.06M | $572.83M |
| Account Payables | $30.51M | $34.09M | $31.77M | $36.53M | $25.44M | $31.97M | $18.83M | $21.98M | $20.50M | $19.96M | $31.07M | $23.84M | $22.21M | $21.66M | $27.75M | $22.99M | $24.36M | $23.17M | $21.71M | $16.51M |
| Short Term Debt | $7.04M | $4.46M | $4.25M | $4.37M | $8.25M | $7.87M | $19.19M | $8.15M | $6.05M | $8.05M | $8.69M | $8.72M | $5.18M | $7.98M | $14.55M | $19.58M | $15.62M | $19.45M | $19.04M | $18.42M |
| Tax Payables | $9.66M | $5.35M | $1.51M | $5.86M | $1.61M | $31.09M | $17.70M | $11.59M | $4.57M | $1.53M | $597.00K | $13.12M | $9.08M | $3.96M | $3.63M | $2.68M | $1.08M | $1.62M | $2.35M | $2.99M |
| Deferred Revenue | $- | $- | $- | $- | $1.61M | $-221.21M | $-217.54M | $- | $- | $- | $-69.91M | $- | $-67.33M | $-67.25M | $- | $- | $-71.15M | $- | $-53.68M | $-48.93M |
| Other Current Liabilities | $126.54M | $115.11M | $99.44M | $208.41M | $190.11M | $187.03M | $195.57M | $63.92M | $63.74M | $72.65M | $63.28M | $68.69M | $67.33M | $64.39M | $78.61M | $81.86M | $71.15M | $52.48M | $50.20M | $45.45M |
| Total Current Liabilities | $173.76M | $159.01M | $136.97M | $255.17M | $225.41M | $257.96M | $251.28M | $105.64M | $94.86M | $102.19M | $103.63M | $114.36M | $103.81M | $97.99M | $124.55M | $127.10M | $112.20M | $96.72M | $93.29M | $83.37M |
| Long Term Debt | $643.51M | $625.39M | $616.34M | $622.75M | $619.30M | $668.40M | $512.69M | $96.87M | $96.53M | $98.38M | $98.55M | $99.84M | $99.48M | $101.02M | $55.02M | $48.28M | $51.65M | $50.44M | $49.15M | $51.64M |
| Deferred Revenue Non-Current | $- | $- | $23.42M | $22.67M | $24.04M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $6.96M | $- | $6.07M | $6.07M | $6.07M | $7.43M | $7.43M | $7.40M | $7.37M | $6.77M | $6.89M | $7.02M | $7.07M | $7.61M | $5.47M | $5.46M | $5.45M | $4.25M | $4.18M | $4.19M |
| Other Non-Current Liabilities | $20.95M | $33.10M | $24.87M | $24.05M | $28.78M | $22.92M | $24.86M | $22.40M | $21.79M | $20.72M | $21.86M | $22.02M | $22.18M | $19.59M | $18.19M | $18.65M | $17.92M | $14.78M | $14.42M | $13.68M |
| Total Non-Current Liabilities | $671.41M | $658.49M | $641.21M | $646.79M | $648.08M | $691.53M | $537.75M | $119.44M | $118.47M | $119.34M | $120.78M | $122.35M | $122.20M | $123.51M | $73.97M | $67.68M | $70.31M | $66.04M | $64.33M | $66.09M |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $845.17M | $817.50M | $778.18M | $901.96M | $873.49M | $949.49M | $789.03M | $225.08M | $213.33M | $221.53M | $224.41M | $236.71M | $226.01M | $221.50M | $198.52M | $194.78M | $182.51M | $162.76M | $157.62M | $149.46M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $6.00K | $6.00K | $6.00K | $6.00K | $6.00K | $6.00K | $6.00K | $6.00K | $6.00K | $6.00K | $6.00K | $6.00K | $6.00K | $6.00K | $6.00K | $6.00K | $5.00K | $5.00K | $5.00K | $5.00K |
| Retained Earnings | $568.79M | $530.82M | $490.39M | $452.44M | $409.27M | $373.10M | $323.88M | $297.75M | $271.72M | $237.81M | $221.94M | $204.59M | $180.34M | $160.58M | $130.58M | $122.81M | $117.77M | $124.05M | $120.13M | $120.32M |
| Accumulated Other Comprehensive Income Loss | $-9.18M | $-8.82M | $-8.83M | $-8.77M | $-8.48M | $-8.41M | $-8.32M | $-8.27M | $-8.62M | $-9.93M | $-8.71M | $-7.25M | $-6.76M | $-6.28M | $-4.93M | $-5.64M | $-3.72M | $-4.48M | $-5.17M | $-5.46M |
| Other Total Stockholders Equity | $172.69M | $205.67M | $231.77M | $228.67M | $238.62M | $230.44M | $273.67M | $259.08M | $265.55M | $277.28M | $286.07M | $282.17M | $271.94M | $275.87M | $296.34M | $288.38M | $288.25M | $285.66M | $282.72M | $262.65M |
| Total Stockholders Equity | $732.30M | $727.68M | $713.35M | $672.36M | $639.42M | $595.14M | $589.24M | $548.58M | $528.66M | $505.17M | $499.31M | $479.52M | $445.52M | $430.18M | $421.99M | $405.56M | $402.31M | $405.23M | $397.68M | $377.51M |
| Total Equity | $732.30M | $727.68M | $713.35M | $672.36M | $639.42M | $595.14M | $589.24M | $548.58M | $528.66M | $505.17M | $499.31M | $479.52M | $445.52M | $430.18M | $467.22M | $450.96M | $448.72M | $450.96M | $442.44M | $423.37M |
| Total Liabilities and Stockholders Equity | $1.58B | $1.55B | $1.49B | $1.57B | $1.51B | $1.54B | $1.38B | $773.66M | $741.99M | $726.70M | $723.72M | $716.24M | $671.53M | $651.68M | $665.75M | $645.74M | $631.24M | $613.72M | $600.06M | $572.83M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $45.23M | $45.40M | $46.42M | $45.73M | $44.76M | $45.86M |
| Total Liabilities and Total Equity | $1.58B | $1.55B | $1.49B | $1.57B | $1.51B | $1.54B | $1.38B | $773.66M | $741.99M | $726.70M | $723.72M | $716.24M | $671.53M | $651.68M | $665.75M | $645.74M | $631.24M | $613.72M | $600.06M | $572.83M |
| Total Investments | $81.03M | $58.38M | $38.10M | $103.57M | $129.92M | $34.07M | $14.54M | $18.04M | $22.08M | $29.53M | $20.30M | $17.70M | $14.30M | $12.21M | $11.74M | $13.53M | $12.98M | $10.87M | $11.10M | $12.20M |
| Total Debt | $650.55M | $629.85M | $620.58M | $627.12M | $623.64M | $672.56M | $528.74M | $102.03M | $102.58M | $103.24M | $103.92M | $105.28M | $104.66M | $106.14M | $66.33M | $64.67M | $67.27M | $66.24M | $64.71M | $66.58M |
| Net Debt | $498.94M | $437.73M | $430.96M | $425.97M | $479.11M | $405.78M | $380.14M | $-74.59M | $-53.52M | $-54.00M | $-62.23M | $-67.35M | $-21.69M | $-474.00K | $-39.10M | $-36.93M | $-25.37M | $-21.67M | $-22.68M | $11.73M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $159.52M | $137.54M | $91.39M | $63.30M | $1.10M |
| Depreciation and Amortization | $52.97M | $41.78M | $28.74M | $26.75M | $25.18M |
| Deferred Income Tax | $-17.87M | $-13.74M | $-15.75M | $4.21M | $1.12M |
| Stock Based Compensation | $24.37M | $20.24M | $17.86M | $18.69M | $20.50M |
| Change in Working Capital | $- | $-24.21M | $-32.18M | $-1.92M | $9.13M |
| Accounts Receivables | $-21.67M | $-26.09M | $-10.13M | $-14.92M | $-20.16M |
| Inventory | $-48.80M | $-1.72M | $-11.75M | $1.26M | $15.30M |
| Accounts Payables | $63.56M | $13.24M | $-736.00K | $3.02M | $14.96M |
| Other Working Capital | $- | $-9.64M | $-9.56M | $8.72M | $-972.00K |
| Other Non Cash Items | $-5.60M | $21.89M | $-878.00K | $-13.03M | $240.00K |
| Net Cash Provided by Operating Activities | $213.39M | $183.50M | $89.18M | $97.99M | $57.27M |
| Investments in Property Plant and Equipment | $-41.04M | $-38.17M | $-24.03M | $-27.46M | $-33.85M |
| Acquisitions Net | $- | $-506.41M | $421.00K | $- | $- |
| Purchases of Investments | $-76.79M | $-144.56M | $-35.76M | $-17.38M | $-13.56M |
| Sales Maturities of Investments | $126.02M | $38.62M | $27.97M | $18.77M | $12.41M |
| Other Investing Activities | $-133.12M | $1.39M | $-1.37M | $-2.61M | $-1.41M |
| Net Cash Used for Investing Activities | $-124.93M | $-649.12M | $-32.78M | $-28.67M | $-36.41M |
| Debt Repayment | $10.17M | $526.34M | $-1.78M | $32.10M | $-880.00K |
| Common Stock Issued | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $-85.46M | $-58.14M | $-39.91M | $-28.87M | $-24.43M |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $-5.67M | $-14.11M | $15.25M | $-40.24M | $23.06M |
| Net Cash Used Provided by Financing Activities | $-80.95M | $454.09M | $-26.44M | $-37.02M | $-2.25M |
| Effect of Forex Changes on Cash | $-190.00K | $-282.00K | $-220.00K | $-223.00K | $352.00K |
| Net Change in Cash | $7.31M | $-11.80M | $29.75M | $32.08M | $18.96M |
| Cash at End of Period | $151.84M | $144.53M | $156.33M | $126.59M | $94.51M |
| Cash at Beginning of Period | $144.53M | $156.33M | $126.59M | $94.51M | $75.55M |
| Operating Cash Flow | $213.39M | $183.50M | $89.18M | $97.99M | $57.27M |
| Capital Expenditure | $-41.04M | $-38.17M | $-24.03M | $-27.46M | $-33.85M |
| Free Cash Flow | $172.34M | $145.34M | $65.15M | $70.54M | $23.41M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $37.96M | $40.43M | $37.95M | $43.18M | $36.17M | $49.22M | $26.12M | $26.03M | $33.91M | $15.87M | $17.35M | $24.25M | $19.76M | $30.96M | $8.62M | $3.96M | $-5.79M | $4.79M | $-1.43M | $3.52M |
| Depreciation and Amortization | $14.66M | $-4.11M | $14.14M | $13.96M | $13.79M | $13.57M | $7.02M | $7.40M | $7.43M | $7.49M | $7.02M | $6.79M | $6.55M | $6.51M | $6.87M | $6.83M | $6.77M | $6.67M | $5.92M | $5.82M |
| Deferred Income Tax | $- | $- | $- | $- | $-12.58M | $-2.60M | $11.49M | $- | $-15.75M | $- | $- | $- | $-961.00K | $5.17M | $- | $- | $-2.52M | $2.00M | $- | $1.64M |
| Stock Based Compensation | $5.63M | $5.60M | $5.78M | $7.36M | $4.62M | $4.64M | $4.87M | $6.11M | $4.30M | $4.30M | $4.24M | $5.02M | $3.85M | $3.92M | $6.08M | $4.83M | $4.33M | $4.37M | $6.51M | $5.28M |
| Change in Working Capital | $-8.59M | $-7.33M | $8.63M | $-7.26M | $-26.75M | $-5.74M | $8.42M | $-139.00K | $-13.85M | $-10.23M | $-25.09M | $17.00M | $11.02M | $-30.43M | $10.28M | $7.20M | $14.02M | $-9.16M | $19.07M | $-14.80M |
| Accounts Receivables | $2.91M | $-8.05M | $6.68M | $-23.20M | $4.09M | $-19.64M | $1.26M | $-11.80M | $-11.55M | $3.60M | $-7.78M | $5.60M | $-755.00K | $-12.18M | $10.09M | $-12.08M | $-13.45M | $-2.25M | $8.03M | $-12.49M |
| Inventory | $-24.47M | $-7.31M | $-7.03M | $-9.99M | $4.81M | $-5.77M | $-1.03M | $268.00K | $1.18M | $-5.50M | $-4.74M | $-2.69M | $7.03M | $-4.11M | $-515.00K | $-1.14M | $12.95M | $-3.41M | $3.52M | $2.24M |
| Accounts Payables | $- | $24.65M | $13.72M | $23.08M | $-3.39M | $6.45M | $2.68M | $5.57M | $-736.00K | $-218.00K | $3.70M | $9.44M | $3.02M | $-14.75M | $-335.00K | $18.88M | $20.61M | $-1.60M | $8.05M | $-5.68M |
| Other Working Capital | $12.97M | $-16.61M | $-4.74M | $2.85M | $-32.26M | $13.22M | $5.51M | $5.82M | $-2.74M | $-8.12M | $-18.16M | $4.65M | $1.74M | $614.00K | $1.04M | $1.55M | $-6.08M | $-1.90M | $-529.00K | $1.12M |
| Other Non Cash Items | $-20.65M | $25.37M | $23.29M | $43.46M | $8.61M | $5.24M | $-3.00M | $982.00K | $-822.00K | $2.95M | $-11.36M | $-2.31M | $218.00K | $-13.56M | $308.00K | $6.00K | $79.00K | $131.00K | $16.00K | $14.00K |
| Net Cash Provided by Operating Activities | $29.02M | $59.96M | $69.11M | $55.29M | $23.86M | $64.33M | $54.92M | $40.38M | $15.23M | $20.38M | $2.81M | $50.77M | $40.44M | $2.57M | $32.16M | $22.82M | $16.89M | $8.81M | $30.09M | $1.48M |
| Investments in Property Plant and Equipment | $-12.41M | $-13.79M | $-6.04M | $-8.79M | $-9.44M | $-10.19M | $-9.05M | $-9.48M | $-6.31M | $-5.62M | $-5.96M | $-6.14M | $-6.88M | $-7.22M | $-5.74M | $-7.62M | $-9.33M | $-5.63M | $-10.89M | $-8.01M |
| Acquisitions Net | $- | $129.00M | $-129.00M | $- | $506.41M | $-5.58M | $-500.83M | $- | $- | $- | $421.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $-29.29M | $-25.96M | $960.00K | $-22.51M | $-91.75M | $-33.03M | $-9.20M | $-10.57M | $-5.19M | $-18.56M | $-6.69M | $-5.32M | $-4.92M | $-5.22M | $-2.74M | $-4.50M | $-13.56M | $- | $- | $-510.00K |
| Sales Maturities of Investments | $7.48M | $5.26M | $65.78M | $47.50M | $-179.00K | $13.65M | $11.09M | $14.06M | $12.50M | $9.07M | $3.86M | $2.54M | $1.35M | $8.95M | $4.53M | $3.94M | $11.45M | $292.00K | $- | $- |
| Other Investing Activities | $-1.47M | $-129.10M | $-636.00K | $-960.00K | $-1.67M | $4.00M | $-586.00K | $-346.00K | $-1.23M | $-145.00K | $192.00K | $-189.00K | $-1.51M | $-279.00K | $-305.00K | $-520.00K | $-740.00K | $-112.00K | $823.00K | $-206.00K |
| Net Cash Used for Investing Activities | $-35.68M | $-34.59M | $-69.90M | $15.24M | $-103.05M | $-31.15M | $-508.58M | $-6.33M | $-229.00K | $-15.26M | $-8.18M | $-9.11M | $-11.95M | $-3.77M | $-4.25M | $-8.70M | $-12.18M | $-5.45M | $-10.07M | $-8.72M |
| Debt Repayment | $4.75M | $9.47M | $-8.03M | $3.98M | $-50.15M | $144.93M | $432.54M | $-968.00K | $-128.00K | $-522.00K | $-593.00K | $-538.00K | $-613.00K | $40.75M | $-6.04M | $-2.00M | $1.31M | $-1.69M | $-1.24M | $739.00K |
| Common Stock Issued | $- | $- | $- | $- | $3.56M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $-42.00M | $-34.96M | $-8.50M | $-17.31M | $58.14M | $-50.00M | $-128.00K | $-8.02M | $-18.07M | $-14.49M | $-6.12M | $-1.23M | $-13.44M | $-6.09M | $-5.56M | $-3.78M | $-3.39M | $-4.33M | $-5.76M | $-10.95M |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $3.41M | $2.67M | $1.00K | $-252.00K | $3.07M | $-8.31M | $-4.30M | $-4.57M | $2.04M | $1.08M | $5.72M | $6.42M | $5.35M | $-51.15M | $6.41M | $-854.00K | $1.85M | $3.00M | $19.45M | $-1.24M |
| Net Cash Used Provided by Financing Activities | $-33.84M | $-22.82M | $-10.72M | $-13.58M | $-47.08M | $86.61M | $428.11M | $-13.55M | $-16.16M | $-13.93M | $-994.00K | $4.65M | $-8.70M | $-16.49M | $-5.19M | $-6.64M | $-227.00K | $-3.03M | $12.46M | $-11.45M |
| Effect of Forex Changes on Cash | $-11.00K | $-63.00K | $-19.00K | $-97.00K | $-238.00K | $-38.00K | $-22.00K | $16.00K | $19.00K | $-99.00K | $-111.00K | $-29.00K | $-48.00K | $-54.00K | $41.00K | $-162.00K | $242.00K | $192.00K | $64.00K | $-146.00K |
| Net Change in Cash | $-40.51M | $2.50M | $-11.53M | $56.85M | $-126.51M | $119.76M | $-25.57M | $20.52M | $-1.15M | $-8.91M | $-6.47M | $46.27M | $19.74M | $-17.75M | $22.75M | $7.33M | $4.73M | $522.00K | $32.54M | $-18.84M |
| Cash at End of Period | $151.84M | $192.35M | $189.85M | $201.38M | $144.53M | $271.04M | $151.28M | $176.85M | $156.33M | $157.48M | $166.39M | $172.86M | $126.59M | $106.84M | $124.59M | $101.84M | $94.51M | $89.78M | $89.25M | $56.71M |
| Cash at Beginning of Period | $192.35M | $189.85M | $201.38M | $144.53M | $271.04M | $151.28M | $176.85M | $156.33M | $157.48M | $166.39M | $172.86M | $126.59M | $106.84M | $124.59M | $101.84M | $94.51M | $89.78M | $89.25M | $56.71M | $75.55M |
| Operating Cash Flow | $29.02M | $59.96M | $69.11M | $55.29M | $23.86M | $64.33M | $54.92M | $40.38M | $15.23M | $20.38M | $2.81M | $50.77M | $40.44M | $2.57M | $32.16M | $22.82M | $16.89M | $8.81M | $30.09M | $1.48M |
| Capital Expenditure | $-12.41M | $-13.79M | $-6.04M | $-8.79M | $-9.44M | $-10.19M | $-9.05M | $-9.48M | $-6.31M | $-5.62M | $-5.96M | $-6.14M | $-6.88M | $-7.22M | $-5.74M | $-7.62M | $-9.33M | $-5.63M | $-10.89M | $-8.01M |
| Free Cash Flow | $16.61M | $46.17M | $63.06M | $46.50M | $14.42M | $54.14M | $45.87M | $30.91M | $8.92M | $14.75M | $-3.15M | $44.63M | $33.56M | $-4.65M | $26.42M | $15.21M | $7.56M | $3.18M | $19.20M | $-6.53M |
Amphastar Pharmaceuticals Dividends
Explore Amphastar Pharmaceuticals's dividend history, including dividend yield, payout ratio, and historical payments.
Dividend Yield
-
Dividend Payout Ratio
-
Dividend Paid & Capex Coverage Ratio
5.20x
Amphastar Pharmaceuticals Dividend History
| Dividend | Adjusted Dividend | Date | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|
| $0.3 | $0.3 | June 11, 2010 | June 30, 2010 | June 07, 2010 | |
| $0.3 | $0.3 | June 11, 2009 | June 30, 2009 | June 05, 2009 |
Amphastar Pharmaceuticals News
Read the latest news about Amphastar Pharmaceuticals, including recent articles, headlines, and updates.
Amphastar Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESS Newswire / April 3, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Dan Dischner, SVP of Corp. Communication, will be participating in an Analyst-Moderated fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9th, 2025, at 1:30 pm ET. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com.
International Medication Systems, Ltd. Receives FDA's Drug Shortage Assistance Award
Recognized for contributions to address shortage of epinephrine injection, 0.1 mg/mL syringes RANCHO CUCAMONGA, CA / ACCESS Newswire / March 28, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) today announced that International Medication Systems, Ltd. ("IMS"), a subsidiary of Amphastar Pharmaceuticals, Inc. ("Amphastar") received a Drug Shortage Assistance Award from the U.S. Food and Drug Administration ("FDA").
Amphastar Pharmaceuticals to Present at the Barclays 27th Annual Global Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESS Newswire / March 5, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations will be presenting at the Barclays 27th Annual Global Healthcare Conference on Wednesday, March 12th, 2025, at 10:30 am ET. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com.
Amphastar Pharmaceuticals, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - AMPH
NEW YORK, NY / ACCESS Newswire / March 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Amphastar Pharmaceuticals, Inc. ("Amphastar Pharmaceuticals, Inc.") (NASDAQ:AMPH) concerning possible violations of federal securities laws. On November 6, 2024, Amphastar received a secondary complete response letter (CRL) from the Food and Drug Administration (FDA) for its generic teriparatide ANDA, AMP-015, following months of delays surrounding the submission of the drug.
AMPH ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Amphastar Pharmaceuticals, Inc. Shareholders Who Lost Money
NEW YORK, NY / ACCESS Newswire / March 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Amphastar Pharmaceuticals, Inc. ("Amphastar Pharmaceuticals, Inc.") (NASDAQ:AMPH) concerning possible violations of federal securities laws. On November 6, 2024, Amphastar received a secondary complete response letter (CRL) from the Food and Drug Administration (FDA) for its generic teriparatide ANDA, AMP-015, following months of delays surrounding the submission of the drug.
Amphastar Pharmaceuticals, Inc. Being Investigated on Behalf of Amphastar Pharmaceuticals, Inc. Investors. Contact Levi & Korsinsky For Details
NEW YORK, NY / ACCESS Newswire / February 28, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Amphastar Pharmaceuticals, Inc. ("Amphastar Pharmaceuticals, Inc.") (NASDAQ:AMPH) concerning possible violations of federal securities laws. On November 6, 2024, Amphastar received a secondary complete response letter (CRL) from the Food and Drug Administration (FDA) for its generic teriparatide ANDA, AMP-015, following months of delays surrounding the submission of the drug.
Amphastar Pharmaceuticals Inc. (AMPH) Q4 2024 Earnings Call Transcript
Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH ) Q4 2024 Earnings Conference Call February 27, 2025 5:00 PM ET Company Participants Dan Dischner - Senior Vice President of Corporate Communications William Peters - Chief Financial Officer & Executive Vice President of Finance Tony Marrs - Executive Vice President of Regulatory Affairs & Clinical Operations Conference Call Participants Jason Gerberry - Bank of America Cerena Chen - Wells Fargo Ekaterina Knyazkova - JPMorgan David Amsellem - Piper Sandler Serge Belanger - Needham & Company Operator Greetings and welcome to the Amphastar Pharmaceuticals Fourth Quarter Earnings Call. At this time, all participants are in a listen-only mode.
Amphastar (AMPH) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Amphastar (AMPH) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2024
Reports Net Revenues of $186.5 Million for the Three Months Ended December 31, 2024 RANCHO CUCAMONGA, CA / ACCESS Newswire / February 27, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months and full year ended December 31, 2024. Fourth quarter Highlights Net revenues of $186.5 million for the fourth quarter GAAP net income of $38.0 million, or $0.74 per share, for the fourth quarter Adjusted non-GAAP net income of $47.2 million, or $0.92 per share, for the fourth quarter Full Year Highlights Net revenues of $732.0 million for the fiscal year GAAP net income of $159.5 million, or $3.06 per share, for the fiscal year Adjusted non-GAAP net income of $200.8 million, or $3.86 per share, for the fiscal year Dr. Jack Zhang, Amphastar's President and Chief Executive Officer, commented: "We are incredibly proud that in 2024, we exceeded our long-term goal of achieving $100 million in annual sales for Primatene MIST®, and we look forward to continuing to grow the brand.
AMPH STOCK ALERT: Levi & Korsinsky Notifies Amphastar Pharmaceuticals, Inc. Investors of an Ongoing Investigation
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Amphastar Pharmaceuticals, Inc. ("Amphastar Pharmaceuticals, Inc.") (NASDAQ:AMPH) concerning possible violations of federal securities laws. On November 6, 2024, Amphastar received a secondary complete response letter (CRL) from the Food and Drug Administration (FDA) for its generic teriparatide ANDA, AMP-015, following months of delays surrounding the submission of the drug.
Levi & Korsinsky Announces an Investigation on Behalf of Amphastar Pharmaceuticals, Inc. (AMPH) Shareholders Who May Have Been Affected by Fraud
NEW YORK, NY / ACCESS Newswire / February 25, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Amphastar Pharmaceuticals, Inc. ("Amphastar Pharmaceuticals, Inc.") (NASDAQ:AMPH) concerning possible violations of federal securities laws. On November 6, 2024, Amphastar received a secondary complete response letter (CRL) from the Food and Drug Administration (FDA) for its generic teriparatide ANDA, AMP-015, following months of delays surrounding the submission of the drug.
Amphastar Pharmaceuticals, Inc. (AMPH) Shareholders May Have Been Affected by Fraud - Levi & Korsinsky Investigates
NEW YORK, NY / ACCESS Newswire / February 24, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Amphastar Pharmaceuticals, Inc. ("Amphastar Pharmaceuticals, Inc.") (NASDAQ:AMPH) concerning possible violations of federal securities laws. On November 6, 2024, Amphastar received a secondary complete response letter (CRL) from the Food and Drug Administration (FDA) for its generic teriparatide ANDA, AMP-015, following months of delays surrounding the submission of the drug.
Investors who Lost Money on Amphastar Pharmaceuticals, Inc. Should Contact Levi & Korsinsky About an Ongoing Investigation - AMPH
NEW YORK, NY / ACCESS Newswire / February 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Amphastar Pharmaceuticals, Inc. ("Amphastar Pharmaceuticals, Inc.") (NASDAQ:AMPH) concerning possible violations of federal securities laws. On November 6, 2024, Amphastar received a secondary complete response letter (CRL) from the Food and Drug Administration (FDA) for its generic teriparatide ANDA, AMP-015, following months of delays surrounding the submission of the drug.
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 27, 2025
RANCHO CUCAMONGA, CA / ACCESS Newswire / February 20, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its Fourth quarter of 2024 ended December 31, 2024, after the market closes on Thursday, February 27, 2025, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
ATTENTION AMPH SHAREHOLDERS: Investors who lost money on Amphastar Pharmaceuticals, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation
NEW YORK, NY / ACCESS Newswire / February 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Amphastar Pharmaceuticals, Inc. ("Amphastar Pharmaceuticals, Inc.") (NASDAQ:AMPH) concerning possible violations of federal securities laws. On November 6, 2024, Amphastar received a secondary complete response letter (CRL) from the Food and Drug Administration (FDA) for its generic teriparatide ANDA, AMP-015, following months of delays surrounding the submission of the drug.
Amphastar Pharmaceuticals: A Gradual Strategy
Amphastar Pharmaceuticals has a growth model based on organic growth and acquisitions, though competition and patent expirations pose risks. Financially, Amphastar has a strong revenue trend but faces potential growth slowdowns, especially in 2025. A fair value estimate derived from a DCF model and backed by a comparison with peers is $43.24, which suggests a 40% upside.
Lost Money on Amphastar Pharmaceuticals, Inc. (AMPH)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
NEW YORK, NY / ACCESS Newswire / February 18, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Amphastar Pharmaceuticals, Inc. ("Amphastar Pharmaceuticals, Inc.") (NASDAQ:AMPH) concerning possible violations of federal securities laws. On November 6, 2024, Amphastar received a secondary complete response letter (CRL) from the Food and Drug Administration (FDA) for its generic teriparatide ANDA, AMP-015, following months of delays surrounding the submission of the drug.
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Amphastar Pharmaceuticals, Inc. (AMPH)
NEW YORK, NY / ACCESS Newswire / February 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Amphastar Pharmaceuticals, Inc. ("Amphastar Pharmaceuticals, Inc.") (NASDAQ:AMPH) concerning possible violations of federal securities laws. On November 6, 2024, Amphastar received a secondary complete response letter (CRL) from the Food and Drug Administration (FDA) for its generic teriparatide ANDA, AMP-015, following months of delays surrounding the submission of the drug.
Amphastar Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / January 8, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jack Zhang, CEO and President, and Bill Peters, CFO will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15th, 2025, at 11:15 am PST.
Amphastar Pharmaceuticals: Cheap With Caveats
Amphastar Pharmaceuticals' stock has declined over 25% since early November, despite solid earnings and sales growth, presenting a potential buying opportunity. Q3 results were impacted somewhat by the effects of Hurricane Helene, after easily exceeding top and bottom-line expectations in Q2. The stock is cheap on a P/E basis, but there are some caveats, including patent expiration in early 2026 on a key product.
Amphastar Pharmaceuticals to Present at the 36th Annual Piper Sandler Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / November 26, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Dan Dischner SVP of Corp. Communication, will participate in an Analyst-Moderated fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Wednesday, December 4th, 2024 at 11:30 am EST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com.
Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / November 13, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will participate in an Analyst-Moderated fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 3:30 pm GMT. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for AMPH.